Dataset Information

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.

ABSTRACT: Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. By single-cell sorting 4,277 SARS-CoV-2 spike protein-specific memory B cells from 14 COVID-19 survivors, 453 neutralizing antibodies were identified. The most potent neutralizing antibodies recognized the spike protein receptor-binding domain, followed in potency by antibodies that recognize the S1 domain, the spike protein trimer, and the S2 subunit. Only 1.4% of them neutralized the authentic virus with a potency of 1-10 ng/mL. The most potent monoclonal antibody, engineered to reduce the risk of antibody-dependent enhancement and prolong half-life, neutralized the authentic wild-type virus and emerging variants containing D614G, E484K, and N501Y substitutions. Prophylactic and therapeutic efficacy in the hamster model was observed at 0.25 and 4 mg/kg respectively in absence of Fc functions.

SUBMITTER: Andreano E

PROVIDER: S-EPMC7901298 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.

Andreano Emanuele E Nicastri Emanuele E Paciello Ida I Pileri Piero P Manganaro Noemi N Piccini Giulia G Manenti Alessandro A Pantano Elisa E Kabanova Anna A Troisi Marco M Vacca Fabiola F Cardamone Dario D De Santi Concetta C Torres Jonathan L JL Ozorowski Gabriel G Benincasa Linda L Jang Hyesun H Di Genova Cecilia C Depau Lorenzo L Brunetti Jlenia J Agrati Chiara C Capobianchi Maria Rosaria MR Castilletti Concetta C Emiliozzi Arianna A Fabbiani Massimiliano M Montagnani Francesca F Bracci Luisa L Sautto Giuseppe G Ross Ted M TM Montomoli Emanuele E Temperton Nigel N Ward Andrew B AB Sala Claudia C Ippolito Giuseppe G Rappuoli Rino R

Cell 20210223 7

Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. By single-cell sorting 4,277 SARS-CoV-2 spike protein-specific memory B cells from 14 COVID-19 survivors, 453 neutralizing antibodies were identified. The most potent neutralizing antibodies recognized the spike protein receptor-binding domain, followed in potency by antibodies ...[more]

PMID: 33667349

Similar Datasets

Project description:IntroductionThe Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are two highly contagious coronaviruses causing MERS and COVID-19, respectively, without an effective antiviral drug and a long-lasting vaccine. Approaches for diagnosis, therapeutics, prevention, etc., particularly for SARS-CoV-2 that is continually spreading and evolving, are urgently needed. Our previous study discovered that >60% of sera from convalescent COVID-19 individuals, but <8% from general population, showed binding activity against the MERS-CoV spike protein, indicating that SARS-CoV-2 infection boosted antibodies cross-reactive with MERS-CoV.MethodsTo generate antibodies specific to both SARS-CoV-2 and MERS-CoV, here we screened 60 COVID-19 convalescent sera against MERS-CoV spike extracellular domain and S1 and S2 subunits. We constructed and characterized monoclonal antibodies (mAbs) from COVID-19 convalescent memory B cells and examined their binding and neutralizing activities against human coronaviruses.Results and discussionOf 60 convalescent serum samples, 34 showed binding activity against MERS-CoV S2, with endpoint titers positively correlated with the titers to SARS-CoV-2 S2. By sorting single memory B cells from COVID-19 convalescents, we constructed 38 mAbs and found that 11 mAbs showed binding activity with MERS-CoV S2, of which 9 mAbs showed potent cross-reactivity with all or a proportion of spike proteins of alphacoronaviruses (229E and NL63) and betacoronaviruses (SARS-CoV-1, SARS-CoV-2, OC43, and HKU1). Moreover, 5 mAbs also showed weak neutralization efficiency against MERS-CoV spike pseudovirus. Epitope analysis revealed that 3 and 8 mAbs bound to linear and conformational epitopes in MERS-CoV S2, respectively. In summary, we have constructed a panel of antibodies with broad-spectrum reactivity against all seven human coronaviruses, thus facilitating the development of diagnosis methods and vaccine design for multiple coronaviruses.

Dataset Information

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.

Publications

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets